Table 1.
Baseline Characteristics and Post-treatment Follow-up
| 1A. Baseline | 1B. Post-treatment Follow-up | |||
|---|---|---|---|---|
| (n=16) | Insulin/Metformin (n=10) | Triple Oral Therapy (n=6) | Insulin/Metformin (n=10) | Triple Oral Therapy (n=6) |
| Age (years) | 45.4 ± 8.32 | 42 ± 7.27 | ||
| Male | 8 | 5 | ||
| Ethnicity: Hispanic | 4 | 5 | ||
| Caucasian | 2 | 1 | ||
| African-American | 4 | 0 | ||
| Statin Use: None | 5 | 3 | 7 | 3 |
| Current | 5 | 3 | 3 | 3 |
| Hepatic Triglyceride Content (%) | 6.59 ± 7.43 | 5.14 ± 5.38 | 7.47 ± 7.40 | 5.26 ± 4.21 |
| Weight (kilograms) | 108.27 ± 19.31 | 95.62 ± 10.35 | 110.94 ± 24.44 | 103.45 ± 4.08 |
| Body mass index | 35.77 ± 4.30 | 34.18 ± 5.42 | 37.13 ± 9.01 | 37.91 ± 4.07 |
| Insulin dose (units) | 64.2 ± 22.0 | 50.3 ± 15.9 | 85.2 ± 60.52 | NA |
| Hemoglobin A1c (%) | 5.99 ± 0.45 | 6.40 ± 0.19 | 6.47 ± 1.20 | 6.70 ± 2.01 |
| Fasting Glucose (mg/dl) | 107.50 ± 20.78 | 121.67 ± 19.79 | 118.00 ± 18.40 | 166.50 ± 122.21 |
| Fasting Insulin (uU/ml) | 35.27 ± 55.55 | 16.97 ± 10.76 | 45.08 ± 36.40 | 5.21 ± 2.06 |
| HOMA-IR | 3.53 ± 4.71 | 1.98 ± 1.21 | 4.95 ± 3.52 | 1.09 ± 1.27 |
| Cholesterol (mg/dl) | 166.7 ± 36.4 | 172.2 ± 23.6 | 160.1 ± 37.6 | 190.8 ± 29.6 |
| Fasting Triglycerides (mg/dl) | 152.9 ± 96.1 | 140.8 ± 75.4 | 180.2 ± 134.5 | 167.0 ± 101.3 |
| Cardiac CRP (mg/l) | 6.00 ± 6.50 | 8.70 ± 11.42 | 8.14 ± 9.94 | 4.89 ± 6.04 |
| Fibrinogen (mg/dl) | 389.1 ± 61.4 | 402.2 ± 95.9 | 429.0 ± 79.7 | 394.3 ± 126.9 |
| Plasminogen activator inhibitor-1 (IU/ml) | 22.56 ± 18.65 | 17.98 ± 8.19 | 18.90 ± 15.08 | 8.06 ± 8.58 |
| Aspartate aminotransferase (U/l) | 16.9 ± 4.84 | 17.2 ± 5.34 | 18.1 ± 4.04 | 13.3 ± 4.50 |